Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In an effort to provide greater flexibility to health care customers, Walgreen ( WAG - Analyst Report ) recently started installing WellHealth EHR, the electronic health record (EHR) solution from Greenway Medical Technologies, Inc. ( GWAY - Snapshot Report ) , a player in the health care information technology (HCIT) market. The drug retail giant has already deployed the EHR in over 200 of its stores and plans to introduce it across 8,000 locations by the summer of next year.
As a part of Walgreen’s HealthCloud initiative, the EHR solution will help the company transform its traditional drugstores to health and daily living destinations. Working as a single patient view of Walgreen, the WellHealth EHR will provide the latest patient immunization and health testing information, along with pharmacy information irrespective of where the patient received the service. The two parties entered into a partnership in 2010 when Walgreen first deployed Greenway’s PrimeSuite in Walgreen’s worksite health centers for primary and acute care.
With the recent verdict of the Supreme Court upholding the Patient Protection and Affordable Care Act of 2010 (PPACA) (also known as Obamacare), the U.S. health care industry is making an all-out effort to rope in hospitals, doctors, pharmacists and others through the EHR and electronic medical records (EMRs).
The recent data shows that the number of hospitals using health information technology (IT) has more than doubled in the last two years. Moreover, nearly 2,000 hospitals and more than 41,000 doctors have received $3.1 billion in incentive payments for ensuring ‘Meaningful Use’ of health IT, particularly, certified EHR. The incentives will be offered for a period of 4–5 years, after which physicians will be penalized for not adopting proper measures.
Notably, “Meaningful Use” is a criterion specified under the EHR incentive program, which is designed to stimulate the use of technology in healthcare. Funded by the HITECH Act, the program enables providers to adopt EHR and meet Meaningful Use needs in order to earn reimbursements and avoid Medicare penalties.
We believe that Walgreen is well placed to gain a meaningful share of the multi-billion dollar American Recovery and Reinvestment Act (ARRA)-related healthcare information technology investment opportunity. We have a long-term Neutral recommendation on Walgreen. The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full reports :
Analyst Report on WAG
Snapshot Report on GWAY